1st International Conference on Polymyxins

2013 Speakers

Robert Bonomo Case Western Reserve University, USA
Otto Cars Uppsala University, Sweden
Marco Cavaleri European Medicines Agency
William Couet Université de Poitiers, France
Dennis Dixon National Institutes of Health, USA
Mike Dudley Rempex Pharmaceuticals, USA
Alan Forrest University at Buffalo, USA
Lena Friberg Uppsala University, Sweden
Helen Giamarellou Athens University, Greece
Niels Høiby University of Copenhagen, Denmark
Keith Kaye Wayne State University, USA
Andrea Kwa Singapore General Hospital, Singapore
Jian Li Monash University, Australia
Johan Mouton Radboud University, The Netherlands
Roger Nation Monash University, Australia
David Paterson University of Queensland, Australia
Mical Paul Rabin Medical Center, Israel
Irene Plank European Commission, Belgium
Fernanda Silveira University of Pittsburgh, USA
Vincent Tam University of Houston, USA
Visanu Thamlikitkul Mahidol University, Thailand
Ursula Theuretzbacher Center for Anti-infective Agents, Austria
Brian Tsuji University at Buffalo, USA
John Turnidge Women's and Children's Hospital, Adelaide, Australia
Claudio Viscoli Università di Genova, Italy
Alexandre Zavascki Federal University of Rio Grande do Sul, Brazil

2013 Program

Thursday 2 May 2013
8:15 – 9:15 Registration

9:15 – 10:00

Chairs
Roger Nation
Jian Li

SESSION 1: Welcome, program overview and introduction to the polymyxins

  • Key features of the polymyxins
    Roger Nation (30 min)
10:00 – 10:30 Morning tea, poster viewing and networking

10:30 – 12:30

Chairs
David Paterson
Otto Cars

SESSION 2: The use of polymyxins in clinical practice

  • Establishing the clinical need for polymyxins
    David Paterson (25 min)
  • Clinical outcomes in polymyxin studies: what are the challenges?
    Fernanda Silveira (15 min)
  • Are polymyxins effective? A meta-analysis of polymyxin use
    Mical Paul (20 min)
  • Snapshots of polymyxin use around the world:
    • North America - Keith Kaye (10 min)
    • South America - Alexandre Zavascki (10 min)
    • Asia - Visanu Thamlikitkul (10 min)
    • Europe - Helen Giamarellou (10 min)
12:30 – 13:45 Lunch, poster viewing and networking

13:45 – 15:45

Chairs
Alan Forrest
Dennis Dixon

SESSION 3: Towards optimized dosing of intravenous colistin and polymyxin B

  • Critical preclinical PK/PD information
    Vincent Tam (15 min)
  • Intravenous polymyxins in critically-ill patients: how can we fit the dose to the patient?
    • Importance of the loading dose: CMS vs polymyxin B
      Lena Friberg (15 min)
    • Selection of individualized maintenance doses for various categories of patients: CMS vs polymyxin B
      Roger Nation (30 min)
  • Dosing in other special patient populations
    Helen Giamarellou (20 min)
  • Risk factors for nephrotoxicity
    Alan Forrest (10 min)
  • Managing patients with declining kidney function and other adverse effects
    Visanu Thamlikitkul (20 min)
15:45 – 16:15 Afternoon tea, poster viewing and networking

16:15 – 18:00

Chairs
Keith Kaye
Ursula Theuretzbacher

SESSION 4: What is the role of inhaled polymyxins for treatment of respiratory tract infections?

  • Inhaled polymyxins: what can we learn from pulmonary delivery of other antibiotics?
    Mike Dudley (20 min)
  • Pulmonary disposition of polymyxins
    William Couet (20 min)
  • Inhalational +/- intravenous administration of polymyxins for treatment of VAP
    Helen Giamarellou (25 min)
  • Use of polymyxins in patients with cystic fibrosis
    Niels Høiby (25 min)
18:00 - 19:30 Reception on the Terrace
Friday 3 May 2013

9:00 – 11:00

Chairs
Brian Tsuji
Fernanda Silveira

SESSION 5: Polymyxins: mono-therapy or a combination?

  • Preclinical approaches: What is important - synergy or activity of combinations?
    Brian Tsuji (20 min)
  • Translational approaches to inform selection of rational combinations for patients
    Alan Forrest (20 min)
  • Clinical trials of monotherapy versus combinations
    • Colistin/fosfomycin - Visanu Thamlikitkul (20 min)
    • Colistin/rifampicin - Claudio Viscoli (20 min)
    • Colistin/carbapenems - Keith Kaye and Johan Mouton (10 min each)
11:00 – 11:30 Morning tea, poster viewing and networking

11:30 – 12:30

Chairs
John Turnidge
Johan Mouton

SESSION 6: Susceptibility and breakpoints

  • In vitro susceptibility testing: what are the critical issues?
    John Turnidge (25 min) 
  • Polymyxin breakpoints: what needs attention?
    Johan Mouton (25 min)
12:30 – 13:45 Lunch, poster viewing and networking

13:45 – 15:00

Chairs
Robert Bonomo
Irene Plank

SESSION 7: Mechanisms of activity, resistance and nephrotoxicity: how understanding may be used advantageously

  • Mechanisms of antibacterial activity
    Brian Tsuji (20 min)
  • Mechanisms of resistance
    Robert Bonomo (20 min)
  • Bacterial biofilm and resistance
    Niels Høiby (15 min)
  • Mechanisms of nephrotoxicity
    Jian Li (15 min)
15:00 – 15:30 Afternoon tea, poster viewing and networking

15:30 – 16:30

Chairs
Otto Cars
Vincent Tam

SESSION 8: Oral presentations of selected abstracts

  • Abstract O-1
    Murat Dizbay (8 min)
  • Abstract O-2
    Claudio Viscoli (8 min)
  • Abstract O-3
    Luisa Sorlí (8 min)
  • Abstract O-4
    Jason Pogue (8 min)

4 min question time after each presentation + 12 min at the end

16:30 – 17:30

Chair
David Paterson

SESSION 9: Colistin and polymyxin B: are they peas in a pod or chalk and cheese?

A lively, entertaining and most importantly informative debate between two teams in which colistin and polymyxin B will be compared and contrasted. Might one have advantages over the other in regard to various considerations? The audience will have an opportunity to vote.

The topics are:

  • The ability to achieve ‘appropriate' plasma concentrations
    Vincent Tam (Poly B team) vs John Turnidge (CMS team)
  • Targeting specific infections (UTI, respiratory, CNS)
    Matti Karvanen (Poly B team) vs William Couet (CMS team) 
  • Clinical effectiveness and adverse effects
    Alexandre Zavascki (Poly B team) vs Keith Kaye (CMS team)

Each team member 5 min and no more than three slides

18:30 – Conference dinner
Saturday 4 May 2013

9:00 – 10:00

Chairs
Ursula Theuretzbacher
William Couet

SESSION 10: Oral presentations of selected abstracts

  • Abstract O-5
    William Couet (8 min)
  • Abstract O-6
    Olivia Bargiacchi (8 min)
  • Abstract O-7
    Teysir Halaby (8 min)
  • Abstract O-8
    Gunther Kern (8 min)

4 min question time after each presentation + 12 min at the end

10:00 – 10:30

Chairs
Dennis Dixon
Irene Plank

SESSION 11: EU and NIH programs facilitating antibacterial resistance research

  • Outlines of the key programs of the NIH and EU will be provided
    Irene Plank and Dennis Dixon
10:30 – 11:00 Morning tea and networking

11:00 – 12:30

Chairs
Roger Nation
Jian Li

SESSION 12: The Prato Polymyxin Consensus 

  • Key topics and issues identified during the preceding symposia will be brought to this session and discussed by a panel, with ample opportunity for input from the audience
  • Recommendations will be made on aspects impacting the future clinical use of polymyxins and high-priority areas for research, and the audience will be asked to vote on whether they do or don't support the recommendations
  • The outcome will be the basis of the Prato Polymyxin Consensus which will summarize high-priority areas requiring attention

Panel members:

David Paterson
Johan Mouton
Keith Kaye
Ursula Theuretzbacher
Brian Tsuji
Mike Dudley
John Turnidge

  • The 2nd International Polymyxin Conference: when and where?
  • Conference close
12:30 – 13:30 Lunch and departure to airport or other